CML
News
Survival differences among AYAs with blood cancers
A new report has revealed differences in survival among adolescents and young adults (AYAs) with hematologic malignancies. The report includes...
News
Marine animals aid development of cytotoxicity assay
Researchers have looked to deep-sea creatures with the goal of creating a better cytotoxicity assay. The team harnessed the power of enzymes...
News
FDA expands indication for bosutinib in newly diagnosed CML
The new indication includes treatment of adult patients with newly diagnosed chronic phase Philadelphia chromosome–positive CML.
News
FDA updates nilotinib product label outlining criteria for discontinuation
CML patients on nilotinib for 3 years or more, and whose leukemia has responded to treatment, may be eligible to discontinue use of nilotinib.
News
Nilotinib label updated with info on discontinuation
The US Food and Drug Administration (FDA) has approved an update to the product label for nilotinib (Tasigna) that includes information about how...
News
FDA expands approved use of bosutinib in CML
The US Food and Drug Administration (FDA) has expanded the approved indication for bosutinib (BOSULIF®). The tyrosine kinase inhibitor (TKI) is...
News
Company launches digital PCR test for monitoring CML
Bio-Rad Laboratories, Inc., has launched the QXDx BCR-ABL %IS Kit, a digital polymerase chain reaction (PCR) test that can monitor molecular...
News
Companies launch generic busulfan in US
Two companies have announced the US launch of a generic busulfan product, Myleran Injection. Mylan NV and Aspen have partnered to develop Myleran...
News
Nilotinib approved to treat kids with CML in EU
The European Commission has approved nilotinib (Tasigna®) for the treatment of pediatric patients. The drug is now approved to treat children age...
Conference Coverage
Cancer patients with TKI-induced hypothyroidism had better survival rates
When it comes to the adverse effects of tyrosine kinase inhibitors, hypothyroidism appears to have a bright side.
News
FDA approves dasatinib for pediatric Ph+ CML
Approval was based on complete cytogenetic response data from 97 pediatric patients with chronic phase CML evaluated in two nonrandomized trials...